During development and repair of bone, two distinct yet complementary mechanisms, intramembranous and endochondral, mediate new bone formation via osteoblasts. Because mechanical bone marrow ablation leads to the rapid and transient formation of new bone in the marrow cavity, we postulated that parathyroid hormone (PTH), which is a bone anabolic hormone, enhances the formation of new bone that forms after marrow ablation. We subjected the left femur of rats to mechanical marrow ablation, or sham operation, and injected the animals daily with PTH or vehicle for 1, 2, or 3 weeks in a first experiment, then with PTH, parathyroid hormone-related peptide (PTHrP), or vehicle for 3 weeks in a second experiment. We subjected both femurs from each rat to soft X-ray, peripheral quantitative computed tomography, computed tomography on a microscale, and histological analysis, and determined the concentration of serum osteocalcin. In addition, in the second experiment, we determined the serum concentration of calcium, tartrate-resistant acid phosphatase (TRAP), and receptor activator of NF-kB ligand (RANKL) at 3 weeks, and subjected femurs to biomechanical testing. Following treatment with PTH or PTHrP for 3 weeks, bone filled the marrow cavity of the shafts whose marrow had been ablated. PTH increased trabecular density in the right femur, but failed to induce bone formation in the medullary region of the right unoperated femoral shafts. The newly formed bone endowed left femoral shafts with improved biomechanical properties when compared to those of right femurs and left femurs from control, shamoperated, and vehicle-treated rats. PTHrP, like PTH, increased serum osteocalcin, but neither increased serum calcium, TRAP, or RANKL at 3 weeks. Our results reveal that the newly formed bone that follows marrow ablation is responsive to PTH, expand the role of PTH in bone, and might open new avenues of investigations to the field of regenerative medicine and tissue engineering. Local bone marrow removal in conjunction with pharmacologic intervention with an anabolic agent might provide a technique for rapid preferential site-directed bone growth in areas of high bone loss.
INTRODUCTION D
URING DEVELOPMENT AND REPAIR OF BONE, two distinct yet complementary mechanisms, intramembranous and endochondral, mediate new bone formation via osteoblasts. After mechanical bone marrow ablation, a distinct sequence of events takes place: a clot forms; the marrow cavity is filled by capillaries, followed by mesenchymal precursor cells; osteoblasts differentiate; and cancellous bone forms. This intramembranous bone formation occurs without a cartilaginous phase, making it distinct from fracture repair in which woven bone replaces regenerated cartilage during endochondral bone formation. The boneformation phase that follows bone marrow ablation is complete by day 7, at which time osteoclasts differentiate in synchrony and resorb the newly formed bone to re-create the marrow cavity into which bone marrow cells repopulate. [1] [2] [3] [4] [5] This transient induction of bone formation in response to marrow ablation has been used as an in vivo model to discover new genes and to investigate the role of known genes in the process of bone formation. [6] [7] [8] [9] [10] [11] We questioned whether parathyroid hormone (PTH) could promote and sustain the formation of new bone that forms following marrow ablation. PTH is a calcium-regulating hormone and was first reported as bone anabolic nearly 30 years ago by Reeve et al. 12, 13 In contrast, parathyroid hormone-related peptide (PTHrP) was initially identified as the humoral factor that causes hypercalcemia of malignancy, [14] [15] [16] and subsequently reported to play a bone anabolic role in humans. 17 PTH and PTHrP target a common receptor.
We report here that PTH and PTHrP promote the formation of bone that is initiated after mechanical marrow ablation in the femur of rats, leading to the replacement of bone marrow by bone in a 3-week treatment time. The newly formed bone endows femurs with improved biomechanical properties. The amount of bone formed in the marrow cavity far exceeds that achievable with marrow ablation or anabolic hormone alone. Since marrow ablation alone results in a transient induction of bone formation that disappears after 2 weeks, it is the combination of the two treatments that is the novel aspect of our findings.
MATERIALS AND METHODS

Animals
Fisher 344 male rats (8-to 10-week-old) with an average weight of 200 g were obtained from Charles River (Kingston, NY). All rats were allowed to rest for 2 weeks after arrival at the Yale Animal Care Facility, and housed under controlled temperature (248C) and light (12 h dark /12 h light) with food and water available ad libitum. The care and treatment of experimental animals complied with NIH guidelines and was approved by the Institutional Animal Care and Use Committee at Yale University.
For bone marrow ablation, rats were anesthetized with a combination of ketamine (50 mg/kg) and xylazine (10 mg/ kg). Hair over the left knee joint was shaved, and the shaved area was cleaned with betadine scrub and then washed with ethanol. A 1.0-cm-long longitudinal skin incision was made across the medial aspect of the knee joint. The distal femur was exposed by lateral luxation of the patella, which was accomplished by release of the medial ligamentous structures. A 1.0-mm hole was drilled through the femoral intracondylar notch above the tendon by a smooth 0.035-inch k-wire drill bit into the marrow cavity. The drilling motion was performed five times. The drill was stopped and pushed further into the marrow cavity to ensure that it went through the growth plate. Drilling was then repeated using a threaded 0.045-inch k-wire drill bit. The content of the bone marrow cavity was back-flushed by injection of 5 ml of normal saline solution into the femur using a syringe attached to a 21-gauge needle. A pipe cleaner (Sharn, Tampa, FL) was used to remove cells and debris from the bone marrow cavity. The medial ligamentous structures were sutured with a 4-0 Dexon thread. The skin incision was closed with surgical metallic clips. The rats were injected i.p. with a 5 ml bolus of saline and were given Carprofen (5 mg/kg/day) for the first 24 h after surgery. Sham animals were subjected to sham operation, in which the skin was excised and the patella exposed, but the femurs were not subjected to bone marrow ablation.
A recombinant analog of human PTH [PTH(1-34)NH 2 ; 40 mg/kg/day] was provided by Unigene Laboratories (Fairfield, NJ). A rat PTHrP analog [PTHrP(1-36)NH 2 ; 40 mg/kg/ day] was obtained from Bachem (Torrence, CA). Phosphatebuffered saline (PBS) and peptides were injected s.c. daily in the dorsal neck region of the animals. Injections were initiated on the day of surgery (day 1) and were performed for 7, 14, or 21 consecutive days between 5:00 p.m. and 8:00 p.m. At the time of sacrifice, rats were anesthetized and blood was collected by cardiac puncture.
In the first series of experiments, rats received four s.c. injections of calcein (10 mg/g body weight; Merck, Darmstadt, Germany) on days 9, 8, 2, and 1 before sacrifice (Table  1) , while in the second series of experiments, rats received two s.c. injections of calcein on days 8 and 1 before sacrifice ( Table 2) . 
Bone radiography
Both excised femurs from each rat were subjected to X-ray using an X-PERT 80 (Kubtec, Fairfield, CT) at 30 kV for 3 s. X-rays were scanned using an Epson Perfection 4870.
Bone densitometry
Bone density was determined as we described previously 18, 19 by peripheral quantitative computed tomography (pQCT) with a Stratec scanner (model XCT Research; Norland Medical Systems, Fort Atkinson, WI). Routine calibration was performed daily with a defined standard that contained hydroxyapatite crystals embedded in lucite, provided by Norland Medical Systems. We scanned 1-mmthick slices located midway between epiphyses, at the center of the femoral shaft. The voxel size was set at 0.1 mm. Scans were analyzed with a software program supplied by the manufacturer (XCT 520, version 5.1). Bone density and geometric parameters were estimated by loop analysis. The lowand high-density threshold settings were 1300 and 2000, respectively. Separation of soft tissue from the outer edge of bone was achieved using contour mode 1. Cortical (high bone density) bone and trabecular (low bone density) bone were separated to obtain trabecular data using peel mode 3.
Computed tomography on a microscale
Both femurs from each rat were scanned with a computed tomography on a microscale (microCT) scanner (MicroCT 40; Scanco, Bassersdorf, Switzerland) with a 2048Â2048 matrix and isotropic resolution of 9 mm 3 (12 mm voxel size). Three-dimensional trabecular measurements in the medullary cavity were made directly.
Biomechanical testing of the femoral midshaft: three-point bending test
Both femurs from each rat were defleshed and subjected to three point bending test by MDS Pharma Services (Bothwell, WA). The anterior-to-posterior diameter at the midpoint of the femoral shaft was taken with an electronic caliper and recorded. Femur was then placed on the lower supports of a three-point bending fixture with the anterior side facing downward in an Instron Mechanical Testing Instrument (Instron 4465 retrofitted to 5500). The span between the two lower supports was set at 14 mm. The upper loading device was aligned to the center of the femoral shaft. The load was applied at a constant displacement rate of 6 mm/min until the femur breaks. The locations of maximal load, stiffness, and energy absorbed were selected manually from the load.
Histology
Femurs were dehydrated in a graded ethanol series and embedded, without decalcification, in methyl methacrylate, as we described previously. 20, 21 Longitudinal 4-micron-thick sections of the distal femurs were obtained on an AutocutÔ microtome equipped with a tungsten carbide blade ( Jung, Reichert, Germany). Eighty-micron-thick cross sections of the femoral shafts were generated with a rotating saw equipped with a tungsten carbide blade (model SP1600; Leica, Wetzlar, Germany). Thin sections were stained with von Kossa stain (pH 3.7), while thick sections were mounted, unstained, and viewed with epifluorescence illumination.
Microscopy
Microscopy was performed using an IMT-2 Olympus microscope equipped with ultraviolet light and an OM-4 camera. We also used a 100 Axiovert 200 M microscope coupled with an LSM510 Meta system (Zeiss Microimaging Systems, Göttingen, Germany).
Biochemical parameters
Concentration of serum calcium was measured using a calcium assay kit (BioAssay Systems, Hayward, CA); serum osteocalcin was determined by radioimmunoassay as described previously. 22 Serum tartrate-resistant acid phosphatase (TRAP) form 5b and receptor activator of NF-kB ligand (RANKL) were captured by ELISA (SBA Sciences, Tykistökatu, Finland, and R & D Systems, Minneapolis, MN, respectively).
Statistical analysis
Data represent the mean AE one standard deviation (SD). Treatment groups were compared using the analysis of variance. Pairwise comparison p-values between the treatment groups were adjusted using Tukey multiple comparison procedure. Statistical significance was declared if the twosided p-value is < 0.05. All computations were performed using the Statistical Analysis System.
RESULTS
All rats gained weight during the course of the experiment, independent of surgery, hormonal treatment, or both in combination (data not shown). This observation suggested that neither surgery nor hormonal treatment affected the health of the animals. X-ray analysis of the femurs revealed radio-opacity in the medullary cavity on days 7 and 14 after marrow ablation, which then decreased to become radiolucent by day 21 . This observation confirmed the transient induction of bone formation as a result of marrow ablation (Fig. 1A) . By contrast, radio-opacity detected 2 weeks after surgery in the ablated femurs tended to increase still further at 3 weeks in the animals that were treated with PTH. Femurs from control and sham-operated animals, like nonoperated FIG. 1. Treatment with PTH extends the bone-formation phase that follows ablation of bone marrow. Shown are results of radiographic, pQCT, and microCT analyses. (A) High-resolution radiograms of the femurs from control, sham-operated, and bone marrowablated (BMX) rats that were treated with PBS or PTH for 7, 14, or 21 consecutive days (n ¼ 5). Note that the marrow cavity of the marrow-ablated (BMX) femurs of rats that were treated with PTH is radio-opaque, indicating the presence of calcified bone. These Xray images are representatives of the overall data. (B) Trabecular and total bone-mineral density of the femoral shafts, as determined by pQCT analysis (trabecular density: p < 0.001 between PTH and every other treatment on day 21). (C) MicroCT analysis of the femoral shafts from the left (operated) and right (nonoperated) femurs from control, sham-operated, and marrow-ablated (BMX) rats treated with PBS or PTH for 21 days. Note the abundance of the newly formed bone in the marrow cavity as a result of marrow ablation and treatment with PTH. 240 femurs, remained unaffected. Together, these data suggest that PTH prolongs the initial bone-formation phase induced by marrow ablation.
We next subjected the femurs from the above-described rats to pQCT analysis to quantitate the effects of hormonal treatment on bone formation, with or without surgery. PTH treatment increased the total bone density as well as the trabecular bone density of the nonoperated distal femurs (data not shown), but did not affect the marrow of the nonablated femoral shafts (Fig. 1A, B) . By contrast, intramedullary bone density of the shafts was transiently increased in response to marrow ablation, and was dramatically and sustainably increased by treatment with PTH (Fig. 1B) . However, due to the lack of clear delineation between the cortical bone and the new bone formed in the marrow, the cortical bone density could not be precisely assessed by pQCT.
To visualize the structural organization of the newly formed bone in the marrow cavity of ablated femurs, we subjected the above-mentioned femoral shafts to microCT analysis, which confirmed the transient induction of new bone formation in the femoral marrow cavity of rats treated with marrow ablation followed by PBS (Fig. 1C) . MicroCT analysis revealed the profound and sustained increase in the amount of new bone formed in response to treatment with PTH. By contrast, the femoral marrow cavity of the right femurs and those from the control and sham-operated rats did not contain any bone (data not shown).
Histologic analysis showed that the newly formed bone had for the most part disappeared from the femoral cavity at day 21, confirming the results of X-ray, pQCT, and microCT analysis (data not shown). By contrast, the ablated bone marrow of rats treated with PTH was progressively replaced by new bone, until day 21 after surgery. That newly formed bone became denser and thicker, while the size of the osteocytic lacunae appeared to decrease with time (Fig. 2) .
We next asked whether PTHrP, which is a bone anabolic hormone, could, like PTH, potentiate the formation of new bone in response to marrow ablation. In the next series of experiments, we subjected the left femurs of young adult male rats to marrow ablation, and sacrificed the rats 3 weeks later. We injected these rats daily with PBS, PTH, or PTHrP, starting on the day of surgery. We included baseline and 3-week controls, as well as sham-operated rats ( Table 2 ). All rats gained weight during the course of the study, independent of surgery or treatment (data not shown), indicating that PTHrP, like PTH, did not affect the health of the animals. X-ray analysis of the femurs confirmed the appearance of strong radio-opacity in the medullary cavity of femurs from rats treated with PTH (Fig.  3A) . The medullary cavity of operated femurs from rats treated with PTHrP was also strongly radio-opaque. The right femurs remained similar to those from control and sham-operated animals. pQCT analysis of these femurs confirmed the potent bone-anabolic effect of both PTH and PTHrP, although the latter was less potent than the former (Fig. 3B) . We confirmed the anabolic effect of PTHrP by microCT analysis (Fig. 3C ; data not shown). As with PTH, the newly formed bone in ablated femurs from rats treated with PTHrP became histologically denser with time (data not shown). In addition, the linearity of the signals by the fluorochrome calcein that had been injected before sacrifice of the animals indicates that the newly formed bone is regular (Fig. 3D, E) .
As anticipated, both PTH and PTHrP augmented the serum concentration of osteocalcin, thus supporting the anabolic role of these hormones in bone (Fig. 4A, B) , but neither altered the serum concentration of calcium or the proosteoclastic cytokine RANKL (Fig. 4C, D) . However, PTH, unlike PTHrP, decreased the serum concentration of TRAP, a biomarker that reflects osteoclastic activity (Fig. 4C) .
To next investigate whether the new bone formed within the marrow cavity alters the structural biomechanical parameters of the femurs, we subjected the right and the left femur from these rats to 3-point bending. PTH, but not PTHrP, increased the maximum load and the stiffness of the left (operated) femoral shafts when compared to those from control and sham-operated animals (Table 3) . Our data support the conclusion that the new bone formed in the marrow cavity in response to PTH possesses structural and mechanical properties that are similar to those of endogenous bone. 
SITE-SPECIFIC BONE FORMATION IN RATS
DISCUSSION
While it is well established that PTH and PTHrP stimulate osteoblasts and augment bone mass, 12,13,17 the abundance of bone formed in response to PTH or PTHrP in the marrow cavity after marrow ablation is far more than that formed in response to either hormone alone without marrow ablation. Indeed, neither PTH nor PTHrP alone induces the formation of new bone in the intact marrow. Hence, we have shown that it is the synergistic effect of mechanical marrow ablation and PTH (and to a lesser extent PTHrP) that allows for this new bone to fill the marrow cavity.
Given that PTH and PTHrP target osteoblasts and increase the turnover of bone with a positive bone balance when administered intermittently for extended times, and given that PTH has been proposed to require functional osteoclasts to exert its anabolic activity, [23] [24] [25] it is of interest that both PTH and PTHrP promote the formation of intramedullary bone after marrow ablation. This anabolic effect was confirmed by the augmentation of the serum biomarker of bone formation osteocalcin by PTH and PTHrP, and the decrease of the bone resorption marker TRAP by PTH. Therefore, our data support a potent and sustained anabolic effect of PTH when given daily for 3 consecutive weeks after marrow ablation. Such a potent anabolic effect of PTH postmarrow ablation might explain the mechanism by which PTH stimulates implant anchorage in low-density trabecular bone. 26 Regarding the lower potency of PTHrP, as compared to PTH, it is possible, based on the serum concentration of TRAP and RANKL, that PTHrP no longer promotes bone formation beyond 2 to 3 weeks, but indeed allows for osteoclastic bone resorption to take over. In this regard, the role of endogenous PTHrP produced by osteoblasts remains to be investigated. 27 It is also possible that the dose of PTHrP used here was suboptimal.
It appears, from our study and from those of others, that bone marrow is a potent inhibitor of bone formation by endosteal cells, which line the entire inner surface of bone, since the ablation of bone marrow leads to the rapid formation of new bone. This newly formed bone is, however, only transiently present since it is spontaneously and rapidly resorbed by osteoclasts to allow for the return of bone marrow cells. While the molecular switch that triggers osteoclast differentiation and activation remains poorly understood, the timing of their differentiation might offer a unique model system to investigate the programming of the endogenous gene circuitry that initiates osteoclastogenesis.
The new bone formed after ablation of the marrow in rats and mice was reported to be immature and irregular in nature and was referred to as woven bone. In contrast, the bone that forms during the last week of a 3-week treatment with PTH or PTHrP after marrow ablation is regular, based on the concentric calcein labels. Unlike trabecular bone, which occupies the epiphyseal marrow cavity, this new bone is not modeled upon a cartilaginous anlagen, but rather undergoes intramembranous development. Indeed, the fate of this new intramedullary bone upon extended treatment with PTH will be important to investigate.
The induction of bone in specific skeletal sites in a timely manner provides a unique source of osteoblast progenitor cells for investigations of upstream molecular events that mediate the formation of bone. Although genes such as those coding for IGF-1 11 and runx2/cbfa1 9 have already 244 been identified as regulated or essential for bone formation in response to marrow ablation, it is now critical that we identify and compare the genes that are sequentially activated by PTH and PTHrP in response to marrow ablation.
Our observation expands the role of PTH, as well as PTHrP, in bone and might open new avenues of investigations to the field of regenerative medicine and tissue engineering. These findings might also be potentially useful for investigations on the molecular mechanisms of intramembranous bone formation. In addition, local bone marrow removal in conjunction with pharmacologic intervention with an anabolic agent may provide a technique for rapid preferential site-directed bone growth in areas of high bone loss. 
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